FDA approves eight week maintenance dosing for Ebglyss in atopic dermatitis

The US Food and Drug Administration cleared a reduced every-eight-week maintenance dosing regimen for Eli Lilly's lebrikizumab (Ebglyss) to treat moderate-to-severe atopic dermatitis. This update allows eligible patients to transition to a schedule of as few as six maintenance injections per year, down from the standard biweekly dosing. The 250 mg dosing option applies to adults and pediatric patients aged 12 years and older who weigh at least 40 kg, or about 88 pounds.

For medical-aesthetic practices that manage chronic skin conditions alongside cosmetic procedures, this shift addresses a major barrier in patient compliance. The extended interval offers a competitive alternative to daily topicals or more frequent biologics, particularly for patients seeking low-maintenance disease control. You can discuss this option with adolescent and adult patients who struggle with the administrative burden of frequent injections, positioning it as a way to maintain clear skin with minimal disruption to their daily routines.

Source: Dermatology Times, https://www.dermatologytimes.com/view/dermatology-times-june-2026-recap